For obsessive-compulsive disorder, depression, panic attacks.

Treatment of Parkinsonism symptoms (tremor, rigidity, extreme restlessness, spastic contractions, and involuntary movements) as well as in the prevention or control of extrapyramidal disorders

Benzodiazepine for short-term relief of excessive anxiety (not associated with everyday life). Also useful as an initial anticonvulsant medication

Tricyclic for depression. Endogenous depressions are more likely to be alleviated than are other depressive states

Quieting emotionally disturbed children and adults

Buspirone provides short-term symptomatic relief of excessive anxiety in generalized anxiety disorder

Part of a total treatment program for Attention Deficit Hyperactivity Disorder (ADHD). This CNS stimulant although structurally different is similar to other stimulants. The exact mechanism and site of action of the drug in man is not known. Peak serum levels after single doses occur within 2 to 4 hours and the serum half-life is approximately 12 hours. In adults steady state is reached in approximately 2 to 3 days. There is some risk for liver damage

Also for simple and complex absence seizures (epileptic)

Trazodone is a psychoactive compound with sedative and anti-depressant properties. Its mechanism of action in humans is not clear

For the control of seizures

Antianxiety agent. Can be used for petit mal, akinetic, and myoclonic seizures, absense seizures

For anxiety, also for withdrawal symptoms of alcoholism

For acute manic episodes in patients with bipolar affective disorders. Maintenance therapy has been found useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a history of mania). Requires careful monitoring as elevated levels can cause kidney damage and even death

Tricyclic antidepressants for endogenous depressive illness including the depressed phase of manic-depressive illness, psychotic depression, and melancholia. May help selected patients suffering severe depressive neurosis. Also exerts a sedative effect for anxiety

For the symptomatic relief of depressive illness. Long-term use (more than 5 to 6 weeks) has not been evaluated. Also shown to significantly reduce the symptoms of obsessive-compulsive disorder.

Monoamine oxidase (MAO) inhibitor, contraindicated in an acute confusional state

Multipurpose Drug. Uses include: anxiety and depression, agitation and confusional states, emotional disturbances, psychosomatic disorders, sleep disturbances, difficulties with concentration, aggressiveness, intractable pain. Particularly useful: in chronic hospitalized psychotic patients, in psychotic outpatients, in geriatric patients suffering from severe agitation anxiety or depression associated with organic brain syndrome, during alcohol withdrawal

Antianxiety agent

Monoamine oxidase (MAO) inhibitor for treatment of atypical, nonendogenous, or neurotic depressed patients. They may show mixed anxiety phobic or hypochondriacal features. Less conclusive evidence of usefulness for severely depressed patients

Useful in the management of schizophrenia and other psychotic disorders. Some patients resistant to medications respond favorably. May help withdrawn and apathetic schizophrenic patients. Not recommended for the treatment of nonpsychotic mental and emotional disorders.

Multipurpose drug. Acute and chronic schizophrenias, manic-depressive syndromes, autonomic disturbances, personality and emotional troubles secondary to physical conditions, in pain due to cancer or phantom limb pains, general anesthesia, as a sedative

Management of chronic schizophrenia that does not include excitement, agitation or hyperactivity. Has relatively little sedative action and is not indicated for mania or acute schizophrenia.

A MAO inhibitor for symptomatic treatment of moderate to severe depression. May be used to treat psychotic depressive states such as: depressive phases of manic-depressive psychosis, involutional melancholia, reactive depressions and psychoneurotic depressions of moderate to severe intensity

Potent serotonin reuptake inhibitor (SSRI) for symptomatic relief of depressive illness. Treatment in patients with moderate to moderately severe depressive disorder is effective for at least 6 months

The maintenance treatment of chronic non-agitated schizophrenic patients.

Long-acting anti-psychotic. Effect generally in 24 to 72 hours after injection with significant effects within 48 to 96 hours. Amelioration of symptoms continues for 1 to 8 weeks with an average duration of 3 to 4 weeks

Antidepressant, also for OCD

For Attention-Deficit Hyperactivity Disorder (ADHD), a mild CNS stimulant. Rapidly absorbed from tablets, however owing to extensive first-pass metabolism, bioavailability is low (approx. 30%) and large individual differences exist (11 to 52%). 78 to 97% of the dose is excreted within 48 to 96 hours. Indicated as an integral part of a total treatment program, is not indicated for all children with this syndrome. Should not be used in children under 6 years of age since safety and efficacy have not been established, suppression of growth (i.e. weight gain and/or height) has been reported with the long-term use of stimulants in children. Therefore monitoring and Drug Holidays are recommended, may lower the convulsive threshold for seizures and should be discontinued if seizures occur

Treatment of acute and chronic schizophrenia, organic brain syndrome and mental retardation associated with psychotic symptoms, treatment of some patients with alcohol withdrawal

For management of schizophrenia. Long term use (more than 6 weeks) has not been evaluated

New Antidepressant: Symptomatic relief of depression. Long-term (more than 6 to 8 weeks) effectiveness is unknown

Antipsychotic as well as tricyclic antidepressant and antiobsessional drug with mild sedative effect which may help alleviate anxiety associated with depression.

For management of psychotic disorders and severe nausea and vomiting in adults. Has not been shown effective for behavioral complications of mental retardation

Anti-anxiety agent - also for acute alcohol withdrawal, skeletal muscle spasm, convulsive disorders

All types of mental depression. Suitable for apathetic withdrawn depressed patients. Schizophrenics may have aggravation of some aspects of their psychosis. A tranquilizer given concurrently will usually provide sufficient control

The control of absence (petit mal) epilepsy. Blood dyscrasias (some with fatal outcome) have been associated use of ethosuximide, periodic blood counts should be performed

Antidepressant unrelated to tricyclic, tetracyclic, or other known antidepressant agents.

Indicated for acute and maintenance treatment of schizophrenia and psychotic disorders. Found to improve both positive and negative symptoms. Effective in maintaining clinical improvement during one year of therapy.